This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

  • August 31, 2026

  • 5 min

Share

  • 1

    Bristol Myers Squibb has terminated its partnership with Cellares for the manufacturing of CAR T-cell therapy Breyanzi.

  • 2

    Cellares disputes Bristol Myers' assessment that its Cell Shuttle platform cannot meet Breyanzi's manufacturing requirements.

  • 3

    The end of the partnership will lead to approximately 100 job cuts at Cellares' facility in South San Francisco.

  • 4

    A first-in-human gene therapy study for sickle cell disease showed faster collection and modification of blood stem cells.

  • 5

    Researchers at St. Jude found that deleting the Regnase-1 gene from CAR T cells improved tumor control in osteosarcoma models.

Original Source(s)

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

  • August 31, 2026

Related Content

Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

Genetic Testing in Retinoblastoma: New Applications

Liquid biopsy and molecular profiling are expanding the diagnostic and prognostic role of genetic testing in retinoblastoma.

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A